US district court strikes down AstraZeneca’s Pulmicort patent

17-02-2015

US district court strikes down AstraZeneca’s Pulmicort patent

yamix / Shutterstock.com

A US court has ruled that an AstraZeneca patent covering asthma inhaler Pulmicort Respules (budesonide inhalation suspension) is invalid, allowing generic drug makers to enter the market with their own versions.


AstraZeneca, Pulmicort Respules, patent infringement, obviousness, generics

LSIPR